Rock Springs Capital KRYS Position
Exited8-Fund ConvergenceRock Springs Capital exited their position in Krystal Biotech Inc. (KRYS) in Q4 2024, after holding the stock for 7 quarters.
The position was first reported in Q2 2023 and has been tracked across 7 quarterly 13F filings.
KRYS is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for KB803 in 259 days (Dec 31, 2026), making the timing of Rock Springs's position particularly relevant.
Short interest stands at 16.4% of float with 9.2 days to cover, indicating significant bearish positioning against the stock.
About Krystal Biotech Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Full company profile →Short Interest
16.4%
9.2 days to cover
Rock Springs Capital KRYS Position History
Frequently Asked Questions
Does Rock Springs Capital own KRYS?
No. Rock Springs Capital exited their position in Krystal Biotech Inc. (KRYS) in Q4 2024. They previously held the stock for 7 quarters.
How many hedge funds own KRYS?
8 specialist biotech hedge funds currently hold KRYS, including Avoro Capital Advisors, Redmile Group, Baker Bros. Advisors and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy KRYS?
Rock Springs Capital's position in KRYS was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's KRYS position increasing or decreasing?
Rock Springs Capital completely exited their KRYS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KRYSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →